Eton Pharmaceuticals initiates ET-700 pilot study for Wilson disease

Eton Pharmaceuticals, Inc.

First patient dosed in double-blinded, placebo-controlled trial comparing ET-700 to Galzin and placebo.
Study uses 64Cu PET imaging to assess intestinal copper absorption in 36 healthy volunteers.
Topline results expected H2 2026; positive data could lead to pivotal study in early 2027.
CEO expects peak annual U.S. sales of ET-700 could exceed $100 million if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.